The mathematical modelling of adjuvant chemotherapy scheduling: Incorporating the effects of protocol rest phases and pharmacokinetics

Bulletin of Mathematical Biology

Volumn 67, Issue 3, 2005, Pages 563-611

  Gaffney, E A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 16344373473     PISSN: 00928240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bulm.2004.09.002     Document Type: Article

References (54)

1. R. Adam Current surgical strategies for the treatment of colorectal cancer liver metastases Eur. J. Cancer Suppl. 2 2004 21 26
2. Z. Agur Resonance and anti-resonance in the design of chemotherapeutic protocols J. Theor. Med. 1 1998 237 245
3. n series for predicting optimal chemotherapy treatment Random Comput. Dyn. 2 1994 279 286
4. Z. Agur, R. Arnon, and B. Schechter Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs Math. Biosci. 92 1988 1 15
5. Z. Agur, R. Arnon, and B. Schechter Effect of the dosing interval on survival and myelotoxicity in mice treated by Cytosine arabinoside Eur. J. Cancer 28A 1992 1085 1090
6. Z. Agur, R. Arnon, B. Sandak, and B. Schechter Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration Exp. Hematol. 19 1991 364 368
7. L.K. Anderson, and M.C. Mackey Resonance in periodic chemotherapy: a case study of acute myelogenous leukaemia J. Theor. Biol. 209 2001 113 130
8. M. Andreeff, D.W. Goodrich, and A.B. Pardee Cell proliferation, differentiation, and apoptosis J.F. Holland D.W. Kufe R.E. Pollack R.R. Weichselsbaum E.I. Frei R.C. Bast Holland-Frei Cancer Medicine 2000 Decker Inc. (Chapter 2)
9. D. Belpomme Diversity of the resistance mechanisms to anticancer cytotoxic drugs M S-Medecine Sciences 7 1991 465 472
10. Brockmann The Pharmacological Basis of Cancer Chemotherapy 1976 Williams and Wilkins Publishers Baltimore pp. 692-710
11. W.R. Bruce, B.E. Meaker, and F.A. Valeriote Comparison of normal hemapoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo J. Nat. Cancer Inst. 37 1966 233 245
12. R. Buzzoni, G. Bonadonna, P. Valagussa, and M. Zambetti Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes J. Clin. Oncol. 9 1991 2134 2140
13. G. Chiorino, J.A.J. Metz, D. Tomasoni, and P. Ubezio Desynchronisation rate in cell populations: mathematical modelling and experimental data J. Theor. Biol. 208 2001 185 199
14. L. Cojocaru, and Z. Agur Theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs Math. Biosci. 109 1992 85 97
15. A.J. Coldman, and J.H. Goldie A model for the resistance of tumour cells to cancer chemotherapeutic agents Math. Biosci. 65 1983 291 307
16. A.J. Coldman, and J.H. Goldie Drug resistance in cancer: mechanisms and models CUP 1998
17. A.J. Coldman, and J.M. Murray Optimal control for a stochastic model of cancer chemotherapy Math. Biosci. 168 2000 187 200
18. R.S. Day Treatment sequencing, asymmetry and uncertainty: protocol strategies for combination chemotherapy Cancer Res. 46 1986 3876 3885
19. S. Deplacido CMF vs alternating CMF/EV in the adjuvant treatment of operable breast-cancer--a single-center randomized clinical-trial (naples gun-3 study) Br. J. Cancer 71 1995 1283 1287
20. B.F. Dibrov Resonance effect in self renewing tissues J. Theor. Biol. 192 1998 15 33
21. B.F. Dibrov, A.M. Zhabotinsky, Y.A. Neyfakh, M.P. Orlova, and L.I. Churikova Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy Math. Biosci. 73 1985 1 31
22. S. Dube, F. Heyen, and M. Jenicek Adjuvant chemotherapy in colorectal cancer Dis. Colon Rectum 40 1997 35 41
23. E.I. Frei, and K.H. Antman Principles of dose, schedule, and combination chemotherapy J.F. Holland D.W. Kufe R.E. Pollack R.R. Weichselsbaum E.I. Frei R.C. Bast Holland-Frei Cancer Medicine 2000 Decker Inc. (Chapter 40)
24. E.A. Gaffney The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling J. Math. Biol. 48 2004 375 422
25. T.A. Gilewski, C. Dang, A. Surbone, and L. Norton Cytokinetics J.F. Holland D.W. Kufe R.E. Pollack R.R. Weichselsbaum E.I. Frei R.C. Bast Holland-Frei Cancer Medicine 2000 Decker Inc. (Chapter 38)
26. J.H. Goldie, and A.J. Coldman Quantitative model for multiple levels of drug resistance in clinical tumours Cancer Treat. Rep. 67 1983 923 931
27. J.H. Goldie, and A.J. Coldman Application of theoretical models to chemotherapy protocol design Cancer Treat. Rep. 70 1986 127 131
28. J.H. Goldie, A.J. Coldman, and G.A. Gudaskas Rationale for the use of alternating non-cross resistant chemotherapy Cancer Treat. Rep. 66 1982 439 449
29. S. Guichard, I. Hennebelle, R. Bugat, and P. Canal Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line Biochem. Pharmacol. 55 1998 667 676
30. L.H. Harnevo, and Z. Agur Drug resistance as a dynamic process in a model for multi-step gene amplification under various levels of selection stringency Cancer Chemother. Pharmacol. 30 1992 469 476
31. T. Ishikawa, M. Utoh, N. Sawada, M. Nishida, Y. Fukase, F. Sekiguchi, and H. Ishitsuka Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate in human cancer xenografts Biochem. Pharmacol. 55 1998 1091 1097
32. N. Kemeny, Y. Huang, A.M. Cohen, W. Shi, and J.A. Conti Hepatic arterial infusion of chemotherapy after resection of hepatic metastases New England J. Med. 341 1999 2039 2048
33. R.M. Mader, M. Muller, and G.G. Steger Resistance to 5-fluorouracil Gen. Pharmacol. 31 1998 661 666
34. R. Midgley, and D.J. Kerr Seminar in colorectal cancer Lancet 353 1999 391 399
35. R. Midgley, and D.J. Kerr ABC of colorectal cancer: adjuvant chemotherapy BMJ 321 2000 1208 1211
36. K.W. Morton, and D.F. Mayers Numerical Solution Of Partial Differential Equations 1994 Cambridge University Press
37. J.M. Murray The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy IMA J. Math. Appl. Med. Biol. 14 1997 283 303
38. S. Nicum, R. Midgley, and D.J. Kerr Chemotherapy for colorectal cancer J. R. Soc. Med. 93 2000 416 419
39. I. Ojima, and C. Ferlini New insights into drug resistance in cancer Chem. Biol. 10 2003 583 589
40. D.A. Rew, and G.D. Wilson Cell production rates in human tissues and tumours and their significance. Part II: clinical data Eur. J. Surg. Oncol. 26 2000 405 417
41. E. Shochat, D. Hart, and Z. Agur Using computer simulations for evaluating the efficacy of breast cancer chemotherapy protocols J. Math. Models Methods Appl. Sci. 9 1999 599 615
42. M. Spielmann, M. Tubiana-Hulin, M. Namer, H. Mansouri, P. Bougnoux, N. Tubiana-Mathieu, V. Lotz, and J.C. Eymard Sequential or alternating administration of docetaxel (taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial Br. J. Cancer 85 2002 692 697
43. R. Stangl, A. Altendorf-Hofmann, R.M. Charnley, and J. Scheele Factors influencing the natural history of colorectal liver metastases Lancet 343 1994 1405 1410
44. T. Takahashi, P.G. Bhide, T. Goto, S. Miyama, and V.S. Caviness Jr Proliferative behavior of the murine cerebral wall in tissue culture: cell cycle kinetics and checkpoints Exp. Neurol. 156 1999 407 417
45. N.C. Tebbutt, E. Cattell, R. Midgley, D. Cunningham, and D.J. Kerr Systemic treatment of colorectal cancer Eur. J. Cancer 38 2002 1000 1015
46. J. Tsurutani, T. Nitta, T. Hirashima, T. Komiya, H. Uejima, H. Tada, N. Syunichi, A. Tohda, M. Fukuoka, and K. Nakagawa Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan Lung Cancer 35 2002 299 304
47. P. Ubezio, G. Tagliabue, B. Schechter, and Z. Agur Increasing 1-D-Arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurement of bone marrow cell kinetics Cancer Res 54 1994 6446 6451
48. E. Van Cutsem, M. Dicato, J. Wils, D. Cunningham, E. Diaz-Rubio, B. Glimelius, D. Haller, P. Johnston, and D.J. Kerr Adjuvant treatment of colorectal cancer current expert opinion derived from the third international conference: perspectives in colorectal cancer, Dublin, 2001 Eur. J. Cancer 38 2002 1429 1436
49. G. Webb Resonance phenomena in cell population chemotherapy models Rocky Mountain J. Math. 20 1990 1195 1216
50. G. Webb A nonlinear cell population model of periodic chemotherapy treatment Recent Trends in Ordinary Differential Equations Series in Applicable Analysis 1992 World Scientific Publishing Company 569 583
51. G. Webb A cell population model of periodic chemotherapy treatment Biomedical Modeling and Simulation 1992 Elsevier Science Publishers 83 92
52. G. Webb, and M. Johnson Resonances in age structured cell population models of periodic chemotherapy Int. J. Appl. Sci. Comput. 3 1996 57 67
53. T.E. Wheldon Mathematical Models in Cancer Research 1988 Adam Hilger Publishers Bristol
54. S.L. Wolfe Introduction to Cell and Molecular Biology 1995 Wadsworth